



(12) **CORRECTED EUROPEAN PATENT SPECIFICATION**

(15) Correction information:
Corrected version no 1 (W1 B1)
Corrections, see
Bibliography INID code(s) 84

(51) Int Cl.:
C07K 14/705 ^(2006.01) **C07K 16/28** ^(2006.01)
C12N 15/113 ^(2010.01) **G01N 33/574** ^(2006.01)

(48) Corrigendum issued on:
10.03.2021 Bulletin 2021/10

(45) Date of publication and mention
of the grant of the patent:
23.12.2020 Bulletin 2020/52

(21) Application number: **16198189.9**

(22) Date of filing: **10.11.2016**

(54) **IMMUNE MODULATORS FOR REDUCING IMMUNE-RESISTANCE IN MELANOMA AND OTHER PROLIFERATIVE DISEASES**

IMMUNOMODULATOREN ZUR REDUZIERUNG DER IMMUNRESISTENZ IN MELANOMEN UND ANDEREN PROLIFERATIVEN ERKRANKUNGEN

MODULATEURS IMMUNITAIRES DE RÉDUCTION D'IMMUNO-RÉSISTANCE DANS UN MÉLANOME ET D'AUTRES MALADIES PROLIFÉRATIVES

(84) Designated Contracting States:
BE CH DE DK FR GB IE LI LU NL SE

(43) Date of publication of application:
16.05.2018 Bulletin 2018/20

(83) **Declaration under Rule 32(1) EPC (expert solution)**

(73) Proprietor: **Deutsches Krebsforschungszentrum**
Stiftung des
Öffentlichen Rechts
69120 Heidelberg (DE)

(72) Inventors:
• **Beckhove, Philipp**
93059 Regensburg (DE)
• **Michels, Tillmann**
93049 Regensburg (DE)
• **Khandelwal, Nisit**
80469 München (DE)
• **Boutros, Michael**
69117 Heidelberg (DE)

• **Breinig, Marco**
69198 Schriesheim (DE)
• **Sorrentino, Antonio**
93051 Regensburg (DE)
• **Volpin, Valentina**
93053 Regensburg (DE)

(74) Representative: **Kuttenkeuler, David**
Boehmert & Boehmert
Anwaltpartnerschaft mbB
Pettenkoferstrasse 22
80336 München (DE)

(56) References cited:
WO-A1-2015/028515 WO-A1-2015/121454
WO-A2-2008/085601 US-A1- 2013 130 379

• **Weizmann Institute of Science: "OR10H1",**
Weizmann Institute of Science , XP002769440,
Retrieved from the Internet:
URL: <http://www.genecards.org/cgi-bin/carddisp.pl?gene=OR10H1&keywords=or10h1>
[retrieved on 2017-04-21]

Note: Within nine months of the publication of the mention of the grant of the European patent in the European Patent Bulletin, any person may give notice to the European Patent Office of opposition to that patent, in accordance with the Implementing Regulations. Notice of opposition shall not be deemed to have been filed until the opposition fee has been paid. (Art. 99(1) European Patent Convention).

- **TOPALIAN SUZANNE L ET AL: "Safety, activity, and immune correlates of anti-PD-1 antibody in cancer", NEW ENGLAND JOURNAL OF MEDICINE, THE - NEJM, MASSACHUSETTS MEDICAL SOCIETY, US, vol. 366, no. 26, 28 June 2012 (2012-06-28), pages 2443-2454, XP002767416, ISSN: 1533-4406**

Remarks:

The file contains technical information submitted after the application was filed and not included in this specification